

FORXIGA® HAS TWO NEW INDICATIONS¹

1

ADD-ON COMBINATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR (CV) RISK FACTORS OR ESTABLISHED CV DISEASE:

FORXIGA (dapagliflozin) is indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of hospitalization for heart failure in adults with T2D mellitus and CV risk factors or established CV disease.

2

HEART FAILURE:

FORXIGA is indicated in adults, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) to reduce the risk of CV death, hospitalization for heart failure and urgent heart failure visit.

READ ABOUT THESE NEW INDICATIONS IN THE FORXIGA PRODUCT MONOGRAPH (JUNE 29, 2020).

↓ **CLICK HERE** ↓

DOWNLOAD THE FORXIGA PRODUCT MONOGRAPH AT FORXIGA.CA

FORXIGA is also indicated in monotherapy for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance; and in adult patients with type 2 diabetes mellitus to improve glycemic control in add-on combination with metformin, a sulfonylurea, metformin and a sulfonylurea, sitagliptin (alone or with metformin) or insulin (alone or with metformin), when metformin alone or the existing therapy listed above, along with diet and exercise, does not provide adequate glycemic control.¹

Please consult the Product Monograph at www.azinfo.ca/forxiga/pm367 for contraindications, warnings and precautions, adverse reactions, drug interactions dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-668-6000.


Pr **forxiga**[®]
(dapagliflozin)

CV: cardiovascular; HFrEF: heart failure with reduced ejection fraction; T2D: type 2 diabetes

REFERENCE: 1. FORXIGA Product Monograph. AstraZeneca Canada Inc. June 29, 2020.

FORXIGA® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc.